Spyre Therapeutics, Inc. Files S-1/A Amendment

TL;DR

<b>Spyre Therapeutics, Inc. has filed an S-1/A amendment, indicating a step in its public offering process.</b>

AI Summary

Spyre Therapeutics, Inc. (SYRE) filed a Amended IPO Registration (S-1/A) with the SEC on February 5, 2024. Spyre Therapeutics, Inc. filed an S-1/A amendment on February 5, 2024. The company's principal executive offices are located in Waltham, MA. Spyre Therapeutics was formerly known as Aeglea BioTherapeutics, Inc., with a name change on March 11, 2015. The filing pertains to the Securities Act of 1933. The company's Standard Industrial Classification is Pharmaceutical Preparations.

Why It Matters

For investors and stakeholders tracking Spyre Therapeutics, Inc., this filing contains several important signals. This S-1/A filing is a crucial step for Spyre Therapeutics as it prepares for a potential public offering, allowing investors to review updated financial and business information. The amendment provides updated details on the company's financial status and business operations, which are essential for potential investors to make informed decisions.

Risk Assessment

Risk Level: — Spyre Therapeutics, Inc. shows moderate risk based on this filing. The filing is an amendment to a registration statement, not a new offering announcement, thus the immediate risk is low.

Analyst Insight

Monitor for further amendments or effectiveness of the registration statement to gauge progress towards a potential public offering.

Key Numbers

• 2024-02-05 — Filing Date (S-1/A filing date)
• 2015-03-11 — Name Change Date (Date of former company name change)

Key Players & Entities

• Spyre Therapeutics, Inc. (company) — Filer name
• Aeglea BioTherapeutics, Inc. (company) — Former company name
• Waltham, MA (location) — Business address
• 0001193125-24-023071 (filing_id) — Accession number
• 333-276251 (filing_id) — SEC file number

Forward-Looking Statements

• Spyre Therapeutics will announce a public offering of securities within the next 3-6 months. (Spyre Therapeutics, Inc.) — medium confidence, target: 2024-08-05
• The capital raised from any offering will primarily fund research and development for new pharmaceutical preparations. (Spyre Therapeutics, Inc.) — medium confidence, target: 2025-02-05

FAQ

Industry Context

Spyre Therapeutics operates within the pharmaceutical preparations industry, focusing on the development and commercialization of therapeutics.

Regulatory Implications

The S-1/A filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed financial statements and business descriptions.
2. Track future SEC filings from Spyre Therapeutics for updates on their public offering status.
3. Research the company's therapeutic pipeline and market potential.

Year-Over-Year Comparison

This is an amendment to a previous filing, indicating ongoing updates to the company's registration statement.

Key Financial Figures

• $0.0001 — Shares") of our common stock, par value $0.0001 per share ("Common Stock") and (ii) 6,0
• $25.86 — ted sale price for our Common Stock was $25.86 per share. An investment in our secur
• $15.0 million — to Immedica Pharma AB ("Immedica") for $15.0 million in upfront cash proceeds and up to $100
• $100.0 million — lion in upfront cash proceeds and up to $100.0 million in contingent milestone payments (the "
• $210 million — 2023 Investors") to raise approximately $210 million in which the June 2023 Investors were i
• $291.08 — Series A Preferred Stock at a price of $291.08 per share. The Asset Acquisition was ap
• $180 m — the "December 2023 Investors") to raise $180 million, in which transaction the Decembe
• $15.00 — 00 shares of Common Stock at a price of $15.00 per share and 150,000 shares of Series
• $600.00 — Series B Preferred Stock at a price of $600.00 per share. The closing of the December
• $700.0 million — ock held by non-affiliates is less than $700.0 million and our annual revenue is less than $10

Filing Documents

• d518298ds1a.htm (S-1/A) — 3398KB
• d518298dex32.htm (EX-3.2) — 127KB
• d518298dex51.htm (EX-5.1) — 7KB
• d518298dex104.htm (EX-10.4) — 69KB
• d518298dex1019.htm (EX-10.19) — 51KB
• d518298dex231.htm (EX-23.1) — 2KB
• d518298dex232.htm (EX-23.2) — 1KB
• d518298dexfilingfees.htm (EX-FILING FEES) — 31KB
• g518298g0202154215941.jpg (GRAPHIC) — 2KB
• g518298g0202154255978.jpg (GRAPHIC) — 4KB
• g518298g08m07.jpg (GRAPHIC) — 64KB
• g518298g40p53.jpg (GRAPHIC) — 141KB
• g518298g61v60.jpg (GRAPHIC) — 89KB
• g518298g68p81.jpg (GRAPHIC) — 92KB
• g518298g78p51.jpg (GRAPHIC) — 116KB
• g518298g81i79.jpg (GRAPHIC) — 34KB
• g518298g82k34.jpg (GRAPHIC) — 103KB
• g518298page001.jpg (GRAPHIC) — 2KB
• g518298page0093a.jpg (GRAPHIC) — 40KB
• g518298page01a.jpg (GRAPHIC) — 3KB
• 0001193125-24-023071.txt (&nbsp;) — 16179KB
• agle-20230930.xsd (EX-101.SCH) — 102KB
• agle-20230930_cal.xml (EX-101.CAL) — 80KB
• agle-20230930_def.xml (EX-101.DEF) — 552KB
• agle-20230930_lab.xml (EX-101.LAB) — 767KB
• agle-20230930_pre.xml (EX-101.PRE) — 712KB
• d518298ds1a_htm.xml (XML) — 2387KB

USE OF PROCEEDS

USE OF PROCEEDS 51

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 52 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 71

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 72

BUSINESS

BUSINESS 73 MANAGEMENT 105

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 110

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 118 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 121 SELLING STOCKHOLDERS 124 PLAN OF DISTRIBUTION 131

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 134 LEGAL MATTERS 139 EXPERTS 140 WHERE YOU CAN FIND MORE INFORMATION 141 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 ABOUT THIS PROSPECTUS This prospectus is part of a registration statement that we filed with the SEC using a "shelf" registration process. Under this shelf registration process, the Selling Stockholders may, from time to time, sell the securities described in this prospectus in one or more offerings. This prospectus contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholders, have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholders are offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. In this prospectus, unless the context otherwise requires, the terms "Spyre," "Aeglea BioTherapeutics, Inc.," the "Company," "we," "us," and "our" refer to Spyre Therapeutics, Inc., a Delaware corporation, and its consolidated subsidiaries. This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners.

View Full Filing

View this S-1/A filing on SEC EDGAR